Aptys Pharmaceuticals receives €750,000 from BPI France for its Metapain project.

In September 2020, Aptys Pharmaceuticals received a €750,000 repayable grant from BPIFRANCE FINANCEMENT to support the development of its pain medicine.

Named Metapain, the project is the result of a collaboration initiated in January 2017 between APTYS Pharmaceuticals and CDMO UNITHER Pharmaceuticals, world leader in the production of sterile single-dose drugs.

The Metapain project aims to market a tablet based on the combination of two non-opioid analgesic molecules. This product represents a new alternative for the treatment of moderate to severe pain. It aims to fill the gap left by the withdrawal of Di-Antalvic in the arsenal of pain treatment. After receiving favourable scientific advice from the EMA on their programme, the partners are preparing an international phase 3 study, which should start at the end of the year.

Biopôle Clermont-Limagne
Phone: +33 473 670 670
Contact: François Boutignon | contact@aptys-pharmaceuticals.com